Functional_JJ plasticity_NN of_IN an_DT antigen-specific_JJ memory_NN CD4_NP T_NN cell_NN population_NN The_DT protective_JJ nature_NN of_IN memory_NN immune_JJ responses_NNS is_VBZ attributed_VBN largely_RB to_TO terminally_RB differentiated_VBN memory_NN T_NN cells_NNS that_WDT retain_VBP memory_NN of_IN the_DT antigen_NN via_IN the_DT antigen_NN receptor_NN and_CC memory_NN of_IN the_DT effector_NN functions_NNS that_WDT initially_RB cleared_VBD the_DT pathogen_NN ._SENT It_PP is_VBZ not_RB known_VBN whether_IN a_DT given_VBN population_NN of_IN antigen-specific_JJ memory_NN T_NN cells_NNS is_VBZ endowed_VBN with_IN functional_JJ flexibility_NN to_TO provide_VB protective_JJ responses_NNS against_IN antigens_NNS reencountered_VBN in_IN different_JJ immunological_JJ contexts_NNS ._SENT Here_RB ,_, we_PP examine_VBP functional_JJ properties_NNS of_IN influenza_NN hemagglutinin_NN (HA)-specific_JJ memory_NN CD4_NP T_NN cells_NNS recovered_VBN from_IN adoptive_JJ hosts_NNS that_WDT received_VBD in_IN vitro-activated_JJ HA-specific_JJ T_NN cell_NN receptor-transgenic_JJ CD4_NP T_NN cells_NNS 2_CD months_NNS to_TO 1_CD year_NN previously_RB ._SENT We_PP demonstrate_VBP that_IN this_DT HA-specific_JJ memory_NN CD4_NP T_NN cell_NN population_NN bearing_VBG a_DT clonal_JJ T_NN cell_NN receptor_NN can_MD produce_VB predominantly_RB T_NN helper_NN 1_CD or_CC T_NN helper_NN 2_CD effector_NN cytokines_NNS depending_VBG on_IN the_DT nature_NN of_IN the_DT recall_NN stimulus_NN ._SENT Our_PP$ findings_NNS reveal_VBP remarkable_JJ functional_JJ plasticity_NN within_IN an_DT antigen-specific_JJ memory_NN T_NN cell_NN population_NN and_CC have_VBP direct_JJ implications_NNS for_IN modulating_VBG memory_NN T_NN cell_NN function_NN in_IN vaccine_NN design_NN and_CC treatments_NNS for_IN autoimmune_JJ diseases_NNS ._SENT The_DT immune_JJ response_NN to_TO pathogens_NNS previously_RB encountered_VBN is_VBZ more_RBR effective_JJ than_IN the_DT primary_JJ immune_JJ response_NN because_IN of_IN an_DT expanded_JJ population_NN of_IN antigen-specific_JJ "_`` memory_NN "_'' T_NN lymphocytes_NNS that_WDT efficiently_RB elicit_VBP effector_NN functions_NNS for_IN antigen_NN clearance_NN ._SENT The_DT protective_JJ nature_NN of_IN memory_NN responses_NNS is_VBZ attributed_VBN largely_RB to_TO terminally_RB differentiated_VBN memory_NN T_NN cells_NNS that_WDT retain_VBP memory_NN of_IN the_DT antigen_NN via_IN the_DT antigen_NN receptor_NN and_CC memory_NN of_IN the_DT effector_NN functions_NNS that_WDT initially_RB cleared_VBD the_DT pathogen_NN ._SENT It_PP is_VBZ unknown_JJ ,_, however_RB ,_, whether_IN a_DT given_VBN memory_NN T_NN cell_NN population_NN can_MD exhibit_VB functional_JJ flexibility_NN to_TO potentially_RB provide_VB protective_JJ responses_NNS against_IN antigens_NNS that_WDT may_MD be_VB reencountered_VBN in_IN an_DT altered_JJ immunological_JJ context_NN ._SENT CD4_JJ T_NN lymphocytes_NNS orchestrate_VBP an_DT immune_JJ response_NN primarily_RB through_IN the_DT types_NNS of_IN effector_NN cytokines_NNS they_PP produce_VBP ._SENT After_IN activation_NN ,_, naive_JJ CD4_NP T_NN cells_NNS differentiate_VBP into_IN T_NN helper_NN types_NNS I_PP (_( Th1_NP )_) or_CC II_NP (_( Th2_NP )_) effector_NN cells_NNS producing_VBG predominantly_RB IFN-gamma_NN or_CC IL-4_NN for_IN initiation_NN of_IN inflammatory_JJ or_CC humoral_JJ responses_NNS ,_, respectively_RB ._SENT A_DT number_NN of_IN factors_NNS such_JJ as_IN alterations_NNS in_IN antigen_NN dose_NN ,_, antigen_NN affinity_NN for_IN the_DT T_NN cell_NN receptor_NN (_( TCR_NP )_) ,_, polarizing_VBG cytokines_NNS ,_, costimulation_NN ,_, and_CC entry_NN into_IN the_DT cell_NN cycle_NN all_RB have_VBP been_VBN shown_VBN to_TO affect_VB generation_NN of_IN Th1_NP and_CC Th2_NP effector_NN cells_NNS from_IN naive_JJ CD4_NP T_NN cell_NN precursors_NNS ._SENT By_IN contrast_NN ,_, little_RB is_VBZ known_VBN concerning_VBG regulation_NN of_IN effector_NN cytokine_NN production_NN from_IN memory_NN T_NN cells_NNS ._SENT Although_IN numerous_JJ studies_NNS have_VBP demonstrated_VBN that_DT restimulation_NN of_IN memory_NN CD4_NP or_CC CD8_NP T_NN cells_NNS with_IN cognate_JJ antigen_NN yields_VBZ the_DT same_JJ cytokine_NN profile_NN observed_VBD in_IN the_DT primary_JJ response_NN ,_, none_NN of_IN these_DT previous_JJ studies_NNS explored_VBD the_DT capacity_NN of_IN the_DT antigen-specific_JJ memory_NN T_NN cell_NN population_NN to_TO alter_VB its_PP$ cytokine_NN profile_NN ._SENT Effector_NN T_NN cells_NNS generated_VBN by_IN in_IN vitro_NN or_CC in_IN vivo_JJ activation_NN have_VBP been_VBN shown_VBN to_TO exhibit_VB varying_VBG degrees_NNS of_IN functional_JJ commitment_NN and_CC flexibility_NN ._SENT Bulk_JJ populations_NNS of_IN Th1_NP and_CC Th2_NP effector_NN cells_NNS generated_VBN in_IN vitro_NN under_IN strongly_RB polarizing_VBG conditions_NNS (_( exogenous_JJ cytokines_NNS )_) maintain_VBP their_PP$ polarity_NN of_IN cytokine_NN production_NN when_WRB restimulated_JJ with_IN cognate_JJ antigen_NN or_CC nonspecifically_RB with_IN phorbol_NN 12-myristate_JJ 13-acetate_JJ /ionomycin_NN ._SENT However_RB ,_, both_CC in_IN vitro-_NN and_CC in_IN vivo-activated_JJ effector_NN Th1_NP and_CC Th2_NP cells_NNS can_MD switch_VB their_PP$ pattern_NN of_IN cytokine_NN production_NN when_WRB restimulated_JJ in_IN conditions_NNS that_WDT drive_VBP the_DT opposing_JJ polarity_NN ._SENT Irreversible_JJ commitment_NN has_VBZ been_VBN shown_VBN to_TO occur_VB only_RB after_IN repeated_JJ antigenic_JJ stimulation_NN in_IN vitro_NN or_CC as_IN a_DT result_NN of_IN chronic_JJ diseases_NNS such_JJ as_IN allergy_NN and_CC long-term_JJ infections_NNS in_IN vivo_RB ._SENT Although_IN it_PP has_VBZ been_VBN shown_VBN that_IN memory_NN T_NN cells_NNS derive_VBP from_IN activated_VBN /effector_NN cell_NN precursors_NNS ,_, it_PP is_VBZ not_RB known_VBN whether_IN the_DT resultant_JJ memory_NN T_NN cell_NN population_NN is_VBZ irreversibly_RB committed_VBN for_IN effector_NN cytokine_NN production_NN ._SENT In_IN this_DT study_NN ,_, we_PP asked_VBD whether_IN a_DT given_VBN population_NN of_IN antigen-specific_JJ memory_NN T_NN cells_NNS could_MD modify_VB their_PP$ effector_NN response_NN ._SENT To_TO address_VB this_DT question_NN ,_, we_PP used_VBD an_DT in_IN vivo_JJ adoptive_JJ transfer_NN system_NN well_RB characterized_VBN in_IN this_DT laboratory_NN to_TO generate_VB influenza_NN hemagglutinin_NN (HA)-specific_JJ memory_NN T_NN cells_NNS bearing_VBG a_DT TCR_NP clonotype_NN specific_NN for_IN a_DT single_JJ HA_NP peptide_NN /MHC_NN class_NN II_NP complex_NN ._SENT We_PP demonstrate_VBP that_IN this_DT HA-specific_JJ memory_NN T_NN cell_NN population_NN can_MD alter_VB its_PP$ pattern_NN of_IN cytokine_NN production_NN in_IN response_NN to_TO changes_NNS in_IN recall_NN antigen_NN dose_NN and_CC TCR-mediated_JJ stimuli_NNS ._SENT Our_PP$ results_NNS suggest_VBP that_IN a_DT proportion_NN of_IN memory_NN CD4_NP T_NN cells_NNS are_VBP not_RB terminally_RB differentiated_VBN in_IN their_PP$ ability_NN to_TO produce_VB effector_NN cytokines_NNS ._SENT Mice_NNS ._SENT |_SYM BALB_NP /c_NN mice_NNS were_VBD obtained_VBN from_IN the_DT National_NP Cancer_NP Institute_NP Biological_NP Testing_NP Branch_NP ,_, and_CC HA-TCR-transgenic_JJ mice_NNS were_VBD maintained_VBN as_IN heterozygotes_NNS in_IN the_DT animal_JJ facility_NN at_IN the_DT University_NP of_IN Maryland_NP School_NP of_IN Medicine_NP ._SENT RAG2-_NP /-_NN mice_NNS on_IN a_DT BALB_NP /c_NN genetic_JJ background_NN purchased_VBN from_IN Taconic_NP Farms_NP were_VBD bred_VBN and_CC maintained_VBN in_IN the_DT animal_JJ facility_NN under_IN sterile_JJ and_CC pathogen-free_JJ conditions_NNS ._SENT Antibodies_NNS and_CC Reagents_NNS ._SENT |_SYM The_DT following_VBG antibodies_NNS were_VBD purified_VBN from_IN culture_NN supernatants_NNS from_IN hybridomas_NNS maintained_VBN in_IN the_DT laboratory_NN :_: C363.29B_NP (_( anti-CD3epsilon_NP ;_: ref._NP )_) ,_, GK1.5_NP (_( anti-CD4_NP ;_: ref._NP )_) ,_, anti-CD8_NP (_( TIB105_NP ,_, American_NP Type_NP Culture_NP Collection_NP )_) ,_, 212.A1_JJ (_( anti-I-Ad_NN )_) ,_, anti-Thy1_NP (_( TIB238_NP ,_, American_NP Type_NP Culture_NP Collection_NP )_) ,_, anti-Mac-1alpha_NP (_( TIB128_NP ,_, American_NP Type_NP Culture_NP Collection_NP )_) ,_, and_CC 6.5_CD (_( anticlonotype_NP HA-TCR_NP ;_: ref._NP )_) conjugated_VBD to_TO biotin_NN (_( Pierce_NP )_) according_VBG to_TO manufacturer_NN recommendations_NNS ._SENT The_DT following_VBG monoclonal_NN antibodies_NNS were_VBD purchased_VBN from_IN BD_NP PharMingen_NP (_( San_NP Diego_NP )_) :_: FITC-_NP and_CC phycoerythrin_JJ (PE)-conjugated_JJ anti-CD25_NN (_( clones_NNS 7D4_JJ and_CC PC61_JJ ,_, respectively_RB )_) ,_, purified_VBD anti-mouse_NP Ly-6G_NP (_( clone_NN RB6_NP --_: 8C5_JJ )_) ,_, PE-conjugated_NP anti-CD4_NP (_( clone_NN GK1.5_NP )_) ,_, purified_VBD anti-CD16_JJ /CD32_NN (_( clone_NN 2.4G2_JJ )_) ,_, FITC-_NP and_CC PE-conjugated_NP anti-IFN-gamma_NP (_( clone_NN XMG1.2_NP )_) ,_, PE-_NP and_CC allophycocyanin-conjugated_JJ anti-IL-4_NN (_( clone_NN 11B11_JJ )_) ,_, PE-_NP and_CC allophycocyanin-conjugated_JJ anti-IL-2_NN (_( clone_NN JES6-SH4_NP )_) ,_, and_CC FITC-_NP ,_, PE-_NP ,_, and_CC allophycocyanin-conjugated_JJ streptavidin_NN ._SENT The_DT HA_NP peptide_NN 110_CD --_: 119_CD of_IN the_DT sequence_NN ,_, SFERFEIFPK_NP ,_, was_VBD synthesized_VBN by_IN the_DT Biopolymer_NP Laboratory_NP ,_, University_NP of_IN Maryland_NP ._SENT Cell_NN Purification_NN ._SENT |_SYM CD4_NP cells_NNS (_( >90_JJ %_NN pure_JJ )_) were_VBD isolated_VBN from_IN HA-TCR_NP spleen_NN by_IN using_VBG immunomagnetic_JJ depletion_NN as_IN described_VBN ._SENT Mitomycin_NP C-treated_NP antigen-presenting_NN cells_NNS (_( APCs_NP )_) were_VBD from_IN BALB_NP /c_NN splenocytes_NNS by_IN complement-mediated_JJ depletion_NN of_IN T_NN cells_NNS as_RB described_VBN ._SENT In_IN Vitro_NP Generation_NP of_IN Effector_NP Cells_NP ._SENT |_SYM Effector_NP CD4_NP T_NN cells_NNS were_VBD generated_VBN from_IN HA-TCR_NP CD4_NP T_NN cells_NNS (_( 1_CD x_SYM 106_CD cells_NNS per_IN ml_NN )_) by_IN incubating_VBG with_IN 5_CD mug_NN /ml_NN HA_NP peptide_NN in_IN the_DT the_DT presence_NN of_IN APC_NP (_( 3_CD x_SYM 106_CD cells_NNS per_IN ml_NN )_) in_IN complete_JJ Clicks_NP medium_NN (_( Irvine_NP Scientific_NP )_) containing_VBG 5_CD %_NN FCS_NN (_( Gemini_NP Biological_NP Products_NP ,_, Calabasas_NP ,_, CA_NP )_) ,_, 50_CD units/ml_NN penicillin_NN /streptomycin_NN (_( GIBCOBRL_NP )_) ,_, 2_CD mM_NP glutamine_NN (_( GIBCO_NP )_) ,_, 10_CD mM_NP Hepes_NP (_( GIBCO_NP )_) ,_, and_CC 50_CD muM_NN beta-mercaptoethanol_NN in_IN 24-well_JJ plates_NNS for_IN 3_CD days_NNS at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_NP humidified_VBD atmosphere_NN as_IN described_VBN ._SENT The_DT resultant_JJ HA-TCR_NP activated_VBD /effector_JJ CD4_NP T_NN cells_NNS were_VBD >95_JJ %_NN pure_JJ with_IN no_DT residual_JJ APC_NP ._SENT Proliferation_NN and_CC Cytokine_NP Assays_NP ._SENT |_SYM CD4_NP T_NN cells_NNS (_( 50,000_CD per_IN well_RB )_) and_CC antigen-presenting_JJ cells_NNS (_( 150,000_CD per_IN well_RB )_) were_VBD incubated_VBN with_IN titrated_VBN amounts_NNS of_IN HA_NP peptide_NN or_CC anti-CD3epsilon_NN antibody_NN in_IN flat-bottomed_JJ 96-well_NN plates_NNS in_IN complete_JJ Clicks_NP medium_NN ._SENT Proliferation_NN was_VBD assessed_VBN after_IN 72_CD h_NN by_IN the_DT addition_NN of_IN 1_CD muCi_NNS (_( 1_CD Ci_NP =_SYM 37_CD GBq_NP )_) of_IN [_SYM 3H]thymidine_JJ (_( 6.7_CD Ci/mmol_NN )_) per_IN well_RB and_CC harvested_VBN after_IN 18_CD h_NN by_IN using_VBG a_DT Tomtec_NP 96-well_NN plate_NN harvester_NN (_( Wallac_NP ,_, Gaithersburg_NP ,_, MD_NP )_) ._SENT Radioactivity_NN was_VBD quantitated_VBN by_IN using_VBG a_DT Microbeta_NP Tri-luxe_NP plate_NN scintillation_NN counter_NN (_( Wallac_NP )_) ._SENT The_DT level_NN of_IN IFN-gamma_NP and_CC IL-4_NN in_IN 48-h_JJ supernatants_NNS from_IN duplicate_JJ cultures_NNS was_VBD measured_VBN by_IN specific_JJ ELISA_NP (_( Endogen_NP ,_, Cambridge_NP ,_, MA_NP )_) as_RB done_VBN previously_RB ._SENT ELISA_NP results_NNS were_VBD analyzed_VBN by_IN using_VBG MICROPLATE_JJ MANAGER_NP software_NN (_( Bio-Rad_NP )_) ._SENT Adoptive_JJ Transfers_NNS and_CC Cell_JJ Purification_NN ._SENT |_SYM Equal_NP numbers_NNS of_IN purified_VBN effector_NN CD4_JJ T_NN cells_NNS and_CC resting_VBG HA-TCR_NP CD4_NP T_NN cells_NNS from_IN naive_JJ HA-TCR_NP mice_NNS (_( 107_CD cells_NNS per_IN 0.5_CD ml_NN of_IN PBS_NP )_) were_VBD injected_VBN into_IN the_DT tail_JJ vein_NN of_IN RAG2-_NP /-_NN mice_NNS as_RB done_VBN previously_RB ._SENT Adoptive_JJ transfer_NN recipient_NN mice_NNS were_VBD killed_VBN 2_CD --_: 12_CD months_NNS posttransfer_NN ,_, and_CC the_DT resultant_JJ memory_NN CD4_NP T_NN cells_NNS were_VBD isolated_VBN by_IN immunomagnetic_JJ depletion_NN with_IN anti-Mac-1alpha_NP ,_, anti-FcgammaR_NP ,_, anti-Ly6G_NN ,_, and_CC anti-MHC_NP II_NP antibodies_NNS followed_VBN by_IN anti-rat_NP IgG-_NP ,_, anti-mouse_NP IgG-_NP ,_, and_CC anti-mouse_NP IgM-coupled_NP magnetic_JJ beads_NNS as_RB described_VBN ._SENT Intracellular_JJ Cytokine_NP Staining_NP (_( ICS_NP )_) ._SENT |_SYM Purified_JJ naive_NN or_CC memory_NN HA-TCR_NP CD4_NP T_NN cells_NNS (_( 106_CD cells_NNS per_IN ml_NN )_) were_VBD cultured_VBN with_IN HA_NP peptide_NN or_CC anti-CD3_NN antibody_NN (_( 5_CD mug_NN /ml_NN )_) and_CC APC_NP (_( 3_CD x_SYM 106_CD cells_NNS per_IN ml_NN )_) in_IN 1-ml_JJ total_JJ volume_NN for_IN 30_CD --_: 40_CD h_NN at_IN 37C_JJ ._SENT Monensin_NP (_( Golgi_NP Stop_NP ,_, BD_NP PharMingen_NP )_) was_VBD added_VBN (_( 4_CD mul_NN /ml_NN )_) for_IN an_DT additional_JJ 6_CD h_NN of_IN culture_NN ._SENT Cells_NNS were_VBD harvested_VBN ,_, centrifuged_VBN through_IN Ficoll_NP ,_, washed_VBN with_IN medium_NN to_TO remove_VB dead_JJ cells_NNS and_CC residual_JJ APC_NP ,_, and_CC resuspended_VBD in_IN 100_CD --_: 150-mul_JJ staining_VBG buffer_NN (_( PBS_NP /5_CD %_NN FCS_NN /0.05_CD %_NN sodium_NN azide_NN )_) containing_VBG Fc-Block_NP (_( CD16_NP /32_CD ,_, PharMingen_NP )_) followed_VBD by_IN surface_NN staining_VBG for_IN 6.5_CD and_CC CD25_NP ._SENT For_IN intracellular_JJ staining_VBG ,_, cells_NNS were_VBD washed_VBN and_CC resuspended_VBN in_IN Cytoperm_NP /Cytofix_NN solution_NN (_( BD_NP PharMingen_NP )_) for_IN 20_CD min_NN on_IN ice_NN and_CC subsequently_RB incubated_VBN on_IN ice_NN for_IN 30_CD --_: 60_CD min_NN with_IN appropriate_JJ dilutions_NNS of_IN anticytokine_NN or_CC isotype_NN control_NN antibodies_NNS in_IN Permwash_NP solution_NN ._SENT Cells_NNS were_VBD washed_VBN in_IN Permwash_NP solution_NN before_IN flow-cytometric_JJ analysis_NN with_IN the_DT FACScallibur_NP equipped_VBN with_IN two_CD lasers_NNS for_IN three-color_NN analysis_NN using_VBG FITC_NP ,_, PE_NP ,_, and_CC allophycocyanin_NN ,_, and_CC analyzed_VBD by_IN using_VBG CELLQUEST_NP software_NN (_( BD_NP ,_, PharMingen_NP )_) ._SENT To_TO address_VB the_DT question_NN of_IN functional_JJ flexibility_NN of_IN an_DT antigen-specific_JJ memory_NN population_NN ,_, we_PP used_VBD an_DT adoptive_JJ transfer_NN system_NN to_TO generate_VB long-lived_JJ memory_NN T_NN cells_NNS from_IN TCR-transgenic_NP CD4_NP T_NN cells_NNS bearing_VBG a_DT clonotypic_JJ TCR_NP (_( 6.5_CD )_) specific_JJ for_IN influenza_NN HA_NP and_CC MHC_NP class_NN II_NP I-Ed_NP (_( HA-TCR_NP ;_: ref._NP )_) ._SENT As_IN we_PP previously_RB demonstrated_VBD ,_, adoptive_JJ transfer_NN of_IN antigen-activated_JJ HA-TCR_NP effector_NN CD4_NP T_NN cells_NNS into_IN T_NN cell-_NN and_CC B_NP cell-deficient_JJ RAG2-_NP /-_NN mice_NNS yields_VBZ substantial_JJ numbers_NNS of_IN memory_NN T_NN cells_NNS that_WDT express_VBP the_DT 6.5_CD TCR_NP ,_, are_VBP small_JJ in_IN size_NN ,_, lose_VBP CD25_NP expression_NN ,_, and_CC mediate_VB potent_JJ recall_NN responses_NNS ._SENT These_DT HA-TCR_NP memory_NN T_NN cells_NNS are_VBP similar_JJ to_TO those_DT generated_VBN in_IN both_DT sublethally_RB irradiated_JJ and_CC unmanipulated_JJ BALB_NP /c_NN mice_NNS (_( refs_NNS ._SENT and_CC ,_, and_CC data_NNS not_RB shown_VBN )_) ,_, yet_RB the_DT use_NN of_IN RAG2-_NP /-_NN hosts_NNS has_VBZ the_DT advantage_NN that_IN all_DT of_IN the_DT T_NN cells_NNS recovered_VBD after_IN time_NN represent_VBP memory_NN cells_NNS generated_VBN from_IN the_DT input_NN activated_VBD /effector_NN T_NN cells_NNS ._SENT We_PP initially_RB assessed_VBD the_DT cytokine_NN profile_NN and_CC activation_NN state_NN of_IN HA-TCR_NP effector_NN CD4_NP T_NN cells_NNS before_IN transfer_NN into_IN adoptive_JJ hosts_NNS ._SENT Effector_NN cells_NNS were_VBD generated_VBN by_IN activating_VBG HA-TCR_NP CD4_NP T_NN cells_NNS with_IN HA_NP peptide_NN and_CC splenic_JJ APCs_NNS for_IN 3_CD days_NNS ,_, in_IN the_DT absence_NN of_IN exogenous_JJ IL-2_NN or_CC polarizing_VBG cytokines_NNS ,_, by_IN using_VBG peptide_NN and_CC APC_NN doses_NNS previously_RB determined_VBN to_TO optimally_RB stimulate_VB HA-TCR_NP CD4_NP T_NN cells_NNS ._SENT The_DT resultant_JJ effector_NN T_NN cells_NNS were_VBD >90_JJ %_NN 6.5+_JJ ,_, uniformly_RB large_JJ in_IN size_NN ,_, and_CC exhibited_VBN up-regulation_NN of_IN CD25_NP (_( IL-2R_NP )_) expression_NN when_WRB compared_VBN with_IN naive_JJ 6.5+_JJ precursors_NNS (_( Fig._NN A_NP ;_: ref._NP )_) ._SENT Functionally_RB ,_, these_DT HA-TCR_NP effector_NN cells_NNS produced_VBD high_JJ levels_NNS of_IN IFN-gamma_NP and_CC low_JJ levels_NNS of_IN IL-4_NN as_IN assessed_VBN by_IN ELISA_NP (_( ref._NP and_CC data_NNS not_RB shown_VBN )_) ._SENT To_TO examine_VB effector_NN cytokine_NN production_NN on_IN the_DT cellular_JJ level_NN during_IN effector_NN generation_NN ,_, we_PP used_VBD ICS_NP to_TO determine_VB the_DT proportion_NN of_IN activated_VBN 6.5+_JJ cells_NNS producing_VBG IFN-gamma_NP and_CC /or_NN IL-4_NN ._SENT Fig._NN B_NN shows_VBZ that_IN during_IN the_DT 6-h_JJ assay_NN ,_, 6.11_CD %_NN of_IN the_DT activated_VBN 6.5+_JJ T_NN cells_NNS produced_VBN IFN-gamma_NP ,_, 0.84_CD %_NN produced_VBN IL-4_NN ,_, and_CC 93_CD %_NN did_VBD not_RB produce_VB effector_NN cytokines_NNS ._SENT These_DT data_NNS indicate_VBP that_IN the_DT majority_NN of_IN activated_VBN HA-TCR_NP CD4_NP T_NN cells_NNS had_VBD not_RB fully_RB differentiated_VBN to_TO produce_VB effector_NN cytokines_NNS in_IN levels_NNS sufficient_JJ to_TO be_VB detected_VBN by_IN ICS_NP ._SENT However_RB ,_, the_DT 6.5+_JJ cytokine-producing_NN cells_NNS were_VBD predominantly_RB Th1-like_JJ and_CC produced_VBD IFN-gamma_NP with_IN a_DT low_JJ proportion_NN of_IN 6.5+_JJ IL-4-producing_JJ Th2-like_JJ cells_NNS ._SENT A_DT negligible_JJ fraction_NN (_( <0.2%)_of IL-4_NN ,_, Fig._NN )_) ,_, similar_JJ to_TO the_DT pattern_NN of_IN cytokine_NN production_NN by_IN the_DT input_NN HA-TCR_NP effector_NN cells_NNS ._SENT By_IN contrast_NN ,_, in_IN response_NN to_TO anti-CD3_JJ stimulation_NN ,_, HA-TCR_NP memory_NN cells_NNS produced_VBD very_RB low_JJ levels_NNS of_IN IFN-gamma_NP yet_CC substantial_JJ levels_NNS of_IN IL-4_NN (_( IL-4_NN >_SYM IFN-gamma_NP ,_, Fig._NN )_) ._SENT As_IN expected_VBN ,_, CD4_NP T_NN cells_NNS recovered_VBN from_IN adoptive_JJ hosts_NNS that_WDT had_VBD received_VBN naive_JJ HA-TCR_NP CD4_NP T_NN cells_NNS 10_CD weeks_NNS or_CC 1_CD year_NN previously_RB ,_, and_CC freshly_RB isolated_VBN naive_JJ HA-TCR_NP CD4_NP T_NN cells_NNS proliferated_VBD but_CC did_VBD not_RB produce_VB significant_JJ levels_NNS of_IN IFN-gamma_NP or_CC IL-4_NN in_IN response_NN to_TO either_DT antigen_NN or_CC antibody_NN stimulation_NN ._SENT These_DT results_NNS indicate_VBP that_IN collectively_RB ,_, HA-TCR_NP memory_NN T_NN cells_NNS exhibit_VBP a_DT Th1-like_JJ pattern_NN of_IN cytokine_NN production_NN in_IN response_NN to_TO antigen_NN and_CC a_DT Th2-like_JJ pattern_NN in_IN response_NN to_TO anti-CD3_JJ stimulation_NN ._SENT Figure_NP 2_CD |_SYM Functional_JJ responses_NNS of_IN differentially_RB stimulated_VBN HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS ._SENT Functional_JJ responses_NNS of_IN differentially_RB stimulated_VBN HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS ._SENT HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS were_VBD recovered_VBN 10_CD weeks_NNS and_CC 1_CD year_NN posttransfer_NN of_IN HA-TCR_NP effector_NN cells_NNS into_IN RAG2-_NP /-_NN adoptive_JJ hosts_NNS ._SENT For_IN controls_NNS ,_, naive_JJ HA-TCR_NP CD4_NP T_NN cells_NNS were_VBD transferred_VBN into_IN RAG2-_NP /-_NN hosts_NNS in_IN parallel_NN ._SENT Memory_NN and_CC naive_JJ CD4_NP T_NN cells_NNS were_VBD restimulated_JJ with_IN 1_CD mug_NN /ml_NN HA_NP peptide_NN (_( black_JJ bars_NNS )_) or_CC 1_CD mug_NN /ml_NN anti-CD3_NN antibody_NN (_( gray_JJ bars_NNS )_) in_IN the_DT presence_NN of_IN mitomycin_NP C-treated_NP APC_NP ._SENT Freshly_RB purified_VBN HA-TCR_NP CD4_NP T_NN cells_NNS (_( marked_VBN Fresh_NP Tg_NP or_CC FTg_NP )_) were_VBD cultured_VBN in_IN parallel_NN ._SENT IFN-gamma_NNS and_CC IL-4_NN content_NN in_IN 48-h_JJ culture_NN supernatants_NNS was_VBD measured_VBN by_IN specific_JJ ELISA_NP ,_, and_CC proliferation_NN was_VBD assessed_VBN by_IN measuring_NN [_SYM 3H]thymidine_JJ incorporation_NN after_IN 72_CD h_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT These_DT results_NNS are_VBP representative_JJ of_IN five_CD different_JJ experiments_NNS ._SENT Because_IN anti-CD3_JJ antibody_NN is_VBZ a_DT potent_JJ activator_NN of_IN T_NN cells_NNS ,_, the_DT biased_VBN production_NN of_IN IL-4_NN by_IN anti-CD3-stimulated_JJ memory_NN T_NN cells_NNS could_MD be_VB caused_VBN by_IN increased_VBN activation_NN strength_NN ._SENT We_PP asked_VBD whether_IN activating_VBG HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS with_IN increased_VBN antigen_NN doses_NNS would_MD result_VB in_IN a_DT Th2-like_JJ pattern_NN of_IN cytokine_NN production_NN ,_, analogous_JJ to_TO findings_NNS demonstrating_VBG that_DT stimulation_NN of_IN naive_JJ CD4_NP T_NN cells_NNS with_IN increased_VBN antigen_NN dose_NN or_CC affinity_NN favored_VBN Th2_NP effector_NN generation_NN ._SENT When_WRB stimulated_VBN with_IN the_DT optimal_JJ dose_NN of_IN 1_CD mug_NN /ml_NN HA_NP peptide_NN ,_, HA-TCR_NP memory_NN cells_NNS produced_VBD high_JJ levels_NNS of_IN IFN-gamma_NP (_( 250_CD ng_NNS /ml_NN )_) and_CC low_JJ levels_NNS of_IN IL-4_NN (_( <2_JJ ng_NNS /ml_NN )_) ;_: however_RB ,_, when_WRB stimulated_VBN with_IN supranormal_JJ HA_NP peptide_NN concentrations_NNS (_( 100_CD mug_NN /ml_NN )_) ,_, HA-TCR_NP memory_NN cells_NNS produced_VBD high_JJ levels_NNS of_IN IL-4_NN comparable_JJ with_IN amounts_NNS produced_VBN by_IN anti-CD3_JJ stimulation_NN (_( 17_CD ng_NNS /ml_NN and_CC 15_CD ng_NNS /ml_NN ,_, respectively_RB )_) (_( Fig._NN Upper_NP )_) ._SENT High_JJ antigen_NN dose_NN also_RB led_VBD to_TO greatly_RB increased_VBN production_NN of_IN IFN-gamma_NP by_IN HA-TCR_NP memory_NN cells_NNS ,_, whereas_IN all_DT doses_NNS of_IN anti-CD3_JJ antibody_NN led_VBN to_TO biased_VBN IL-4_NN production_NN (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT data_NNS suggest_VBP that_IN although_IN memory_NN T_NN cells_NNS seem_VBP to_TO have_VB varying_VBG thresholds_NNS for_IN cytokine_NN synthesis_NN ,_, the_DT biased_VBN IL-4_NN production_NN revealed_VBN by_IN anti-CD3-mediated_JJ stimulation_NN is_VBZ not_RB caused_VBN merely_RB by_IN activation_NN strength_NN ._SENT Figure_NP 3_CD |_SYM Cytokine_JJ production_NN from_IN HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS in_IN response_NN to_TO increasing_VBG antigen_NN doses_NNS ._SENT Cytokine_JJ production_NN from_IN HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS in_IN response_NN to_TO increasing_VBG antigen_NN doses_NNS ._SENT Memory_NP CD4_NP T_NN cells_NNS were_VBD isolated_VBN from_IN adoptive_JJ hosts_NNS 6_CD months_NNS posttransfer_NN and_CC activated_VBN with_IN the_DT indicated_JJ doses_NNS of_IN HA_NP peptide_NN or_CC 1_CD mug_NN /ml_NN anti-CD3_NN antibody_NN in_IN the_DT presence_NN of_IN APC_NP ._SENT IFN-gamma_NNS and_CC IL-4_NN content_NN in_IN culture_NN supernatants_NNS was_VBD quantitated_VBN by_IN specific_JJ ELISA_NP as_RB described_VBD for_IN Fig._NN ._SENT We_PP therefore_RB asked_VBD whether_IN the_DT change_NN in_IN cytokine_NN production_NN by_IN the_DT HA-TCR_NP memory_NN T_NN cell_NN population_NN in_IN response_NN to_TO anti-CD3_NN was_VBD caused_VBN by_IN preferential_JJ stimulation_NN of_IN a_DT persisting_VBG nonclonotype_NN (_( 6.5-_CD )_) population_NN or_CC a_DT reduced_VBN ability_NN of_IN anti-CD3_NN to_TO activate_VB memory_NN T_NN cells_NNS ._SENT We_PP thus_RB used_VBD ICS_NP to_TO analyze_VB cytokine_JJ production_NN on_IN the_DT cellular_JJ level_NN in_IN conjunction_NN with_IN TCR_NP and_CC activation_NN markers_NNS ._SENT Representative_NP ICS_NP results_NNS are_VBP shown_VBN in_IN Fig._NN ,_, and_CC a_DT summary_NN of_IN ICS_NP results_NNS from_IN memory_NN CD4_NP T_NN cells_NNS isolated_JJ 2_CD --_: 5_CD months_NNS posttransfer_NN is_VBZ shown_VBN in_IN Table_NP ._SENT Because_IN memory_NN CD4_NP T_NN cells_NNS require_VBP restimulation_NN to_TO elicit_VB effector_NN function_NN ,_, we_PP cultured_VBD HA-TCR_NP memory_NN T_NN cells_NNS before_IN adding_VBG a_DT Golgi_NP protein_NN transport_NN inhibitor_NN for_IN intracellular_JJ entrapment_NN of_IN cytokines_NNS (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT Figure_NP 4_CD |_SYM ICS_NP analysis_NN of_IN differentially_RB stimulated_VBN naive_JJ and_CC memory_NN HA-TCR_NP CD4_NP T_NN cells_NNS ._SENT ICS_NP analysis_NN of_IN differentially_RB stimulated_VBN naive_JJ and_CC memory_NN HA-TCR_NP CD4_NP T_NN cells_NNS ._SENT HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS isolated_VBN from_IN adoptive_JJ hosts_NNS 3_CD months_NNS previously_RB were_VBD reactivated_VBN with_IN HA_NP peptide_NN (_( antigen_NN )_) or_CC anti-CD3_NN in_IN the_DT presence_NN of_IN APC_NP followed_VBD by_IN incubation_NN with_IN monensin_NN ,_, surface_NN staining_VBG for_IN 6.5_CD and_CC CD25_NP ,_, and_CC intracellular_JJ staining_VBG for_IN IFN-gamma_NP ,_, IL-4_NN ,_, and_CC IL-2_NP ._SENT (_( A_NP )_) Production_NN of_IN IFN-gamma_NP from_IN 6.5_CD TCR-expressing_NP and_CC CD25+_NP memory_NN T_NN cells_NNS gated_VBN on_IN large_JJ ,_, activated_VBN cells_NNS ._SENT Unactivated_JJ T_NN cells_NNS showed_VBD no_DT IFN-gamma_NP production_NN ,_, and_CC quadrants_NNS are_VBP designated_VBN based_VBN on_IN staining_VBG with_IN isotype-matched_JJ control_NN antibodies_NNS for_IN each_DT cytokine_NN ._SENT Numbers_NNS in_IN quadrants_NNS refer_VBP to_TO the_DT percentage_NN of_IN total_JJ activated_VBN cells_NNS ._SENT (_( B_NP )_) Production_NN of_IN IL-4_NN from_IN 6.5+_JJ and_CC CD25+_NP HA-TCR_NP memory_NN CD4_NP T_NN cells_NNS ._SENT The_DT numbers_NNS in_IN parentheses_NNS refer_VBP to_TO the_DT absolute_JJ number_NN of_IN cells_NNS in_IN each_DT quadrant_NN ._SENT Activation_NN of_IN naive_JJ HA-TCR_NP CD4_NP T_NN cells_NNS yielded_VBD negligible_JJ numbers_NNS of_IN IL-4-producing_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT (_( C_NP )_) IL-4+_NP and_CC IFN-gamma+_NP memory_NN T_NN cells_NNS shown_VBN together_RB ._SENT The_DT numbers_NNS in_IN parentheses_NNS indicates_VBZ absolute_JJ cell_NN number_NN ._SENT (_( D_NP )_) IL-2_NP and_CC IFN-gamma_NP production_NN from_IN 6.5+_JJ activated_VBN naive_NN and_CC memory_NN CD4_NN T_NN cells_NNS ._SENT The_DT numbers_NNS in_IN parentheses_NNS refer_VBP to_TO the_DT absolute_JJ numbers_NNS of_IN 6.5+_JJ T_NN cells_NNS ,_, and_CC data_NNS shown_VBN are_VBP gated_VBN on_IN 6.5+_JJ CD4+_NP T_NN cells_NNS ._SENT Table_NP 1_CD |_SYM Summary_NN of_IN ICS_NP analysis_NN of_IN memory_NN CD4_NP T_NN cells_NNS isolated_VBN from_IN RAG2-/-_NP adoptive_JJ hosts_NNS that_WDT had_VBD received_VBN HA-TCR_NP 6.5+_JJ effector_NN T_NN cells_NNS 2_CD --_: 5_CD months_NNS previously_RB By_IN ICS_NP analysis_NN ,_, striking_JJ differences_NNS are_VBP seen_VBN in_IN the_DT proportion_NN of_IN activated_VBN 6.5+_JJ memory_NN CD4_NP T_NN cells_NNS that_WDT produce_VBP IFN-gamma_NP or_CC IL-4_NN in_IN response_NN to_TO antigen_NN versus_CC anti-CD3_JJ stimulation_NN in_IN the_DT presence_NN of_IN APC_NP ._SENT Stimulation_NN with_IN HA_NP peptide_NN resulted_VBD in_IN a_DT much_RB higher_JJR proportion_NN of_IN 6.5+_JJ IFN-gamma-producing_JJ memory_NN T_NN cells_NNS compared_VBN with_IN anti-CD3_JJ stimulation_NN (_( 9.04_CD versus_IN 1.11_CD %_NN ,_, Fig._NN A_NP )_) ,_, with_IN an_DT average_NN of_IN 8.6-fold_NN more_RBR 6.5+_JJ /IFN-gamma+_NN cells_NNS generated_VBN by_IN antigen_NN compared_VBN with_IN anti-CD3_JJ stimulation_NN (_( see_VB Table_NP )_) ._SENT Naive_JJ 6.5+_JJ T_NN cells_NNS ,_, as_IN expected_VBN ,_, produced_VBD negligible_JJ IFN-gamma_NP in_IN response_NN to_TO either_DT stimulus_NN (_( Fig._NN A_NP )_) ,_, as_RB did_VBD unstimulated_JJ memory_NN T_NN cells_NNS cultured_VBN with_IN APC_NP alone_RB (_( data_NNS not_RB shown_VBN )_) ._SENT To_TO ensure_VB that_IN these_DT differences_NNS in_IN IFN-gamma_NP production_NN were_VBD not_RB caused_VBN by_IN differences_NNS in_IN the_DT extent_NN of_IN activation_NN ,_, we_PP analyzed_VBD the_DT activated_VBN CD25+_NP population_NN for_IN IFN-gamma_NP production_NN ._SENT As_IN shown_VBN in_IN the_DT second_JJ row_NN of_IN Fig._NN A_NP ,_, both_DT antigen_NN and_CC anti-CD3_NN activated_VBD the_DT vast_JJ majority_NN of_IN HA-TCR_NP naive_NN and_CC memory_NN CD4_NN T_NN cells_NNS as_RB assessed_VBN by_IN CD25_NP up-regulation_NN ._SENT In_IN response_NN to_TO HA_NP peptide_NN ,_, 11_CD %_NN of_IN these_DT activated_VBN CD25+_NP memory_NN cells_NNS produced_VBN IFN-gamma+_NP ;_: however_RB ,_, in_IN response_NN to_TO anti-CD3_JJ stimulation_NN ,_, only_RB 2_CD %_NN of_IN CD25+_NP memory_NN cells_NNS produced_VBN IFN-gamma+_NP (_( Fig._NN A_NP )_) ._SENT As_IN expected_VBN ,_, CD25+_NP T_NN cells_NNS generated_VBN by_IN activation_NN of_IN naive_JJ CD4_NP T_NN cells_NNS with_IN either_DT stimulus_NN produced_VBD negligible_JJ IFN-gamma+_NP (_( Fig._NN A_NP )_) ._SENT We_PP also_RB observed_VBD differences_NNS in_IN the_DT proportion_NN of_IN 6.5+_JJ IL-4-producing_NN cells_NNS in_IN response_NN to_TO antigen_NN versus_CC anti-CD3_NN stimulation_NN ._SENT Although_IN a_DT low_JJ fraction_NN of_IN 6.5+_JJ IL-4-producing_NN cells_NNS were_VBD generated_VBN in_IN response_NN to_TO antigen_NN (_( 0.45_CD %_NN ,_, Fig._NN B_NN )_) ,_, a_DT greater_JJR proportion_NN of_IN 6.5+_JJ IL-4+_NP cells_NNS (_( 2.28_CD %_NN ,_, Fig._NN B_NN )_) were_VBD generated_VBN in_IN response_NN to_TO anti-CD3_JJ stimulation_NN ._SENT This_DT increased_VBN IL-4_NN production_NN derived_VBN primarily_RB from_IN 6.5+_JJ memory_NN CD4_NP T_NN cells_NNS ,_, because_IN very_RB few_JJ nonclonotype_NN 6.5-IL-4+_JJ T_NN cells_NNS were_VBD observed_VBN (_( Fig._NN B_NN )_) ._SENT As_IN shown_VBN in_IN Table_NP ,_, we_PP consistently_RB observed_VBD an_DT increase_NN (_( average_JJ of_IN 2.4-fold_NN )_) in_IN the_DT proportion_NN of_IN 6.5+_JJ /IL-4+_NN activated_VBN memory_NN T_NN cells_NNS produced_VBN by_IN anti-CD3_NN compared_VBN with_IN antigen_NN stimulation_NN ._SENT Similarly_RB ,_, we_PP found_VBD an_DT increase_NN in_IN CD25+_NP /IL-4+_JJ memory_NN T_NN cells_NNS generated_VBN in_IN response_NN to_TO anti-CD3_JJ stimulation_NN (_( 3.44_CD %_NN or_CC 270_CD cells_NNS ,_, Fig._NN B_NN )_) versus_CC HA_NP stimulation_NN (_( 1.4_CD %_NN or_CC 79_CD cells_NNS ,_, Fig._NN B_NN )_) ._SENT Few_JJ dual-producing_NN IFN-gamma+_NP /IL-4+_JJ memory_NN T_NN cells_NNS are_VBP observed_VBN in_IN response_NN to_TO either_DT stimulus_NN (_( Fig._NN C_NP )_) ,_, consistent_JJ with_IN enzyme-linked_JJ immunospot_NN results_NNS demonstrating_VBG single_JJ cytokine_NN production_NN from_IN polyclonal_JJ mouse_NN memory_NN CD4_NP T_NN cells_NNS generated_VBN in_IN vivo_RB ._SENT The_DT ICS_NP results_NNS shwon_NN in_IN Fig._NN and_CC Table_NP collectively_RB demonstrate_VBP that_IN HA-specific_JJ memory_NN T_NN cells_NNS can_MD produce_VB different_JJ patterns_NNS of_IN effector_NN cytokines_NNS depending_VBG on_IN the_DT recall_NN stimulus_NN :_: In_IN response_NN to_TO antigen_NN ,_, the_DT ratio_NN of_IN HA-specific_NP IFN-gamma_NP versus_CC IL-4-producing_JJ memory_NN cells_NNS ranged_VBD from_IN 5.7_CD to_TO 20_CD ,_, indicating_VBG a_DT Th1-like_JJ profile_NN ,_, and_CC in_IN response_NN to_TO anti-CD3_JJ stimulation_NN ,_, the_DT ratio_NN of_IN IFN-gamma-_NP to_TO IL-4-producing_JJ memory_NN T_NN cells_NNS was_VBD always_RB less_JJR than_IN 1.0_CD ,_, indicating_VBG the_DT predominance_NN of_IN IL-4-producing_JJ memory_NN cells_NNS and_CC a_DT Th2-like_JJ profile_NN ._SENT Given_VBN the_DT functional_JJ flexibility_NN of_IN the_DT HA-TCR_NP memory_NN population_NN ,_, we_PP asked_VBD whether_IN "_`` nonpolarized_JJ "_'' memory_NN T_NN cells_NNS producing_VBG IL-2_NP were_VBD present_JJ within_IN this_DT memory_NN T_NN cell_NN pool_NN ._SENT As_IN shown_VBN in_IN Fig._NN D_NP ,_, the_DT proportion_NN of_IN IL-2-producing_JJ 6.5+_JJ cells_NNS was_VBD low_JJ for_IN both_DT anti-CD3_NN and_CC antigen-activated_JJ memory_NN T_NN cells_NNS (_( 1_CD --_: 2_CD %_NN )_) ._SENT Dual-producing_NP IFN-gamma+_NP /IL-2+_JJ 6.5+_JJ memory_NN T_NN cells_NNS occurred_VBD in_IN response_NN to_TO antigen_NN at_IN a_DT low_JJ frequency_NN (_( 1.24_CD %_NN )_) but_CC not_RB in_IN response_NN to_TO anti-CD3_JJ stimulation_NN (_( Fig._NN D_NP )_) ._SENT Activation_NN of_IN naive_JJ CD4_NP T_NN cells_NNS resulted_VBN in_IN similar_JJ proportions_NNS of_IN 6.5+_JJ IL-2+_NN in_IN response_NN to_TO antigenic_JJ or_CC anti-CD3-mediated_JJ stimulation_NN (_( 2_CD %_NN for_IN both_DT )_) ._SENT These_DT results_NNS show_VBP that_IN IL-2_JJ producers_NNS do_VBP not_RB represent_VB a_DT large_JJ proportion_NN of_IN the_DT HA-TCR_NP memory_NN T_NN cell_NN pool_NN ._SENT Our_PP$ results_NNS demonstrate_VBP that_IN a_DT memory_NN CD4_NP T_NN cell_NN population_NN derived_VBN from_IN a_DT common_JJ activated_VBN /effector_NN T_NN cell_NN pool_NN and_CC bearing_VBG a_DT clonotype_JJ TCR_NP specific_NN for_IN influenza_NN HA_NP can_MD produce_VB either_DT Th1_NP or_CC Th2_NP effector_NN cytokines_NNS in_IN response_NN to_TO different_JJ recall_NN stimuli_NNS ._SENT In_IN this_DT system_NN ,_, antigen_NN activation_NN led_VBD to_TO the_DT predominant_JJ production_NN of_IN IFN-gamma_NP ,_, anti-CD3_JJ activation_NN led_VBN to_TO the_DT predominant_JJ production_NN of_IN IL-4_NN ,_, and_CC high-dose_NN antigen_NN activation_NN stimulated_VBN production_NN of_IN both_DT IFN-gamma_NP and_CC IL-4_NN ._SENT Our_PP$ results_NNS indicate_VBP remarkable_JJ heterogeneity_NN and_CC plasticity_NN in_IN cytokine_NN production_NN within_IN a_DT population_NN of_IN influenza-specific_JJ memory_NN T_NN cells_NNS and_CC suggest_VBP that_IN memory_NN T_NN cell_NN function_NN can_MD be_VB modulated_VBN in_IN antipathogen_NP immune_JJ responses_NNS and_CC autoimmune_JJ diseases_NNS ._SENT The_DT overall_JJ pattern_NN of_IN effector_NN cytokine_NN production_NN by_IN antigen-activated_JJ 6.5+_JJ HA-TCR_NP memory_NN T_NN cells_NNS was_VBD similar_JJ to_TO that_DT of_IN the_DT input_NN activated_VBD /effector_NN cells_NNS from_IN which_WDT they_PP derived_VBD ,_, with_IN a_DT higher_JJR proportion_NN of_IN IFN-gamma_NP producers_NNS than_IN IL-4_NN producers_NNS ._SENT This_DT result_NN is_VBZ consistent_JJ with_IN results_NNS of_IN others_NNS demonstrating_VBG that_DT restimulation_NN of_IN memory_NN T_NN cells_NNS with_IN cognate_JJ antigen_NN leads_VBZ to_TO the_DT same_JJ pattern_NN of_IN cytokine_NN production_NN as_IN the_DT precursor_NN effector_NN cells_NNS ._SENT In_IN response_NN to_TO anti-CD3_JJ stimulation_NN ,_, known_VBN to_TO differ_VB qualitatively_RB from_IN antigen_NN stimulation_NN ,_, there_EX was_VBD a_DT dramatic_JJ curtailment_NN in_IN IFN-gamma_NP production_NN by_IN activated_VBN memory_NN cells_NNS ,_, concomitant_JJ with_IN an_DT increase_NN in_IN IL-4-producing_JJ memory_NN T_NN cells_NNS ._SENT This_DT biased_VBN IL-4_NN production_NN by_IN anti-CD3-stimulated_JJ memory_NN T_NN cells_NNS is_VBZ consistent_JJ with_IN findings_NNS by_IN Bluestone_NP and_CC coworkers_NNS showing_VBG that_DT anti-CD3_NN promotes_VBZ increased_VBN IL-4_NN production_NN by_IN activated_VBN Th2_JJ cells_NNS while_IN it_PP triggers_VBZ inactivation_NN or_CC deletion_NN of_IN activated_VBN Th1_JJ cells_NNS ._SENT A_DT therapeutic_JJ potential_NN for_IN using_VBG anti-CD3_NN for_IN in_IN vivo_JJ modulation_NN of_IN memory_NN T_NN cell_NN function_NN in_IN diseases_NNS is_VBZ suggested_VBN by_IN the_DT recent_JJ demonstration_NN that_IN anti-CD3_JJ treatment_NN of_IN patients_NNS with_IN autoimmune_JJ diabetes_NN [_SYM known_VBN to_TO involve_VB Th1_JJ effectormemory_JJ T_NN cells_NNS ]_SYM lessened_VBN disease_NN severity_NN ._SENT When_WRB stimulated_VBN with_IN high_JJ doses_NNS of_IN antigen_NN ,_, there_EX was_VBD a_DT dramatic_JJ increase_NN in_IN both_DT IL-4_NN and_CC IFN-gamma_NP production_NN ,_, suggesting_VBG heterogeneity_NN in_IN activation_NN threshold_NN in_IN this_DT clonotypic_JJ 6.5+_JJ memory_NN T_NN cell_NN population_NN ._SENT Heterogeneity_NN in_IN cytokine_NN production_NN by_IN polyclonal_JJ human_JJ memory_NN T_NN cells_NNS has_VBZ been_VBN demonstrated_VBN in_IN response_NN to_TO different_JJ antigen_NN doses_NNS ,_, most_RBS likely_JJ because_IN of_IN memory_NN cells_NNS expressing_VBG TCR_NP with_IN different_JJ antigen_NN affinities_NNS ._SENT Our_PP$ findings_NNS that_IN high-dose_NN antigen_NN stimulation_NN leads_VBZ to_TO increased_VBN IL-4_NN production_NN from_IN clonotypic_JJ memory_NN T_NN cells_NNS are_VBP reminiscent_JJ of_IN findings_NNS that_IN stimulation_NN of_IN TCR-transgenic_NP naive_JJ CD4_NP T_NN cells_NNS with_IN supranormal_JJ antigen_NN doses_NNS leads_VBZ to_TO increased_VBN IL-4_NN secretion_NN ,_, and_CC suggests_VBZ that_IN the_DT functional_JJ fate_NN of_IN resting_JJ memory_NN T_NN cells_NNS may_MD be_VB subject_JJ to_TO similar_JJ influences_NNS of_IN antigen_NN dose_NN and_CC signal_NN strength_NN ._SENT Our_PP$ demonstration_NN that_IN the_DT cytokine_NN profile_NN of_IN HA-TCR_NP memory_NN T_NN cells_NNS could_MD be_VB altered_VBN by_IN the_DT recall_NN stimulus_NN strongly_RB suggests_VBZ that_IN a_DT proportion_NN of_IN memory_NN cells_NNS are_VBP uncommitted_JJ for_IN cytokine_NN production_NN and_CC therefore_RB not_RB terminally_RB differentiated_VBN ._SENT Undifferentiated_JJ human_NN and_CC mouse_NN memory_NN phenotype_NN cells_NNS that_WDT produce_VBP IL-2_NN have_VBP been_VBN identified_VBN and_CC can_MD be_VB generated_VBN under_IN suboptimal_JJ antigen_NN stimulation_NN conditions_NNS ._SENT Although_IN we_PP did_VBD not_RB detect_VB a_DT significant_JJ fraction_NN of_IN HA-TCR_NP memory_NN cells_NNS solely_RB producing_VBG IL-2_NP (_( Fig._NN D_NP )_) ,_, it_PP is_VBZ likely_JJ that_IN the_DT majority_NN of_IN the_DT input_NN activated_VBD /effector_NN cells_NNS had_VBD not_RB fully_RB differentiated_VBN to_TO produce_VB effector_NN cytokines_NNS despite_IN having_VBG acquired_VBN an_DT activated_VBN cell-surface_NN phenotype_NN ._SENT Therefore_RB ,_, we_PP hypothesize_VBP that_IN the_DT HA-TCR_NP memory_NN T_NN cell_NN population_NN consists_VBZ of_IN cells_NNS in_IN various_JJ stages_NNS of_IN functional_JJ commitment_NN depending_VBG on_IN the_DT differentiation_NN state_NN of_IN the_DT activated_VBN /effector_NN T_NN cell_NN from_IN which_WDT they_PP derived_VBD ._SENT For_IN example_NN ,_, the_DT memory_NN 6.5+_JJ cells_NNS that_WDT produced_VBD IFN-gamma_NP in_IN response_NN to_TO both_DT antigen_NN and_CC anti-CD3_JJ stimuli_NNS (_( 1_CD --_: 2_CD %_NN ,_, see_VBP Table_NN )_) may_MD derive_VB from_IN irreversibly_RB committed_VBN effector_NN cells_NNS ,_, whereas_IN the_DT activated_VBN memory_NN 6.5+_JJ cells_NNS that_WDT produce_VBP IFN-gamma_NP in_IN response_NN to_TO antigen_NN but_CC not_RB anti-CD3_JJ stimulation_NN may_MD derive_VB from_IN uncommitted_JJ activated_VBN cells_NNS ._SENT It_PP will_MD be_VB necessary_JJ to_TO sort_VB activated_VBN T_NN cells_NNS expressing_VBG different_JJ levels_NNS of_IN effector_NN cytokines_NNS before_IN transfer_NN to_TO precisely_RB determine_VB the_DT origin_NN of_IN these_DT "_`` uncommitted_JJ "_'' memory_NN T_NN cells_NNS ._SENT Mechanisms_NNS controlling_VBG memory_NN T_NN cell_NN cytokine_NN production_NN are_VBP not_RB known_VBN ,_, although_IN the_DT molecular_JJ basis_NN of_IN Th1_NP and_CC Th2_NP effector_NN generation_NN from_IN naive_JJ T_NN cells_NNS has_VBZ been_VBN elucidated_VBN ._SENT The_DT transcription_NN factors_NNS T-bet_NP and_CC GATA-3_NP have_VBP been_VBN found_VBN necessary_JJ and_CC sufficient_JJ for_IN Th1_NP and_CC Th2_NP generation_NN ,_, respectively_RB ,_, and_CC transcription_NN of_IN the_DT genes_NNS encoding_VBG IFN-gamma_NP and_CC IL-4_NN is_VBZ marked_VBN by_IN reconfiguring_VBG of_IN chromatin_NN structure_NN in_IN these_DT gene_NN loci_NNS ._SENT Assessing_VBG the_DT maintenance_NN or_CC loss_NN of_IN these_DT molecular_JJ changes_NNS during_IN the_DT activated_VBN /effector-to-memory_JJ transition_NN in_IN vivo_JJ is_VBZ likely_JJ to_TO provide_VB insight_NN into_IN mechanisms_NNS for_IN the_DT functional_JJ commitment_NN of_IN memory_NN T_NN cells_NNS ._SENT In_IN summary_NN ,_, we_PP have_VBP identified_VBN both_DT functional_JJ heterogeneity_NN and_CC plasticity_NN in_IN a_DT single_JJ antigen-specific_JJ memory_NN CD4_NP T_NN cell_NN population_NN ._SENT We_PP and_CC others_NNS have_VBP also_RB identified_VBN memory_NN T_NN cell_NN heterogeneity_NN in_IN tissue_NN distribution_NN ,_, homing_NN ,_, and_CC chemokine_NN receptor_NN expression_NN that_WDT correlates_VBZ with_IN functional_JJ differences_NNS ._SENT This_DT memory_NN cell_NN heterogeneity_NN on_IN several_JJ levels_NNS suggests_VBZ that_IN the_DT greater_JJR effectiveness_NN of_IN the_DT anamnestic_JJ response_NN may_MD depend_VB ,_, in_IN part_NN ,_, on_IN the_DT plasticity_NN of_IN the_DT memory_NN T_NN cell_NN population_NN in_IN its_PP$ ability_NN to_TO home_NN to_TO multiple_JJ tissue_NN sites_NNS and_CC fine-tune_VB functional_JJ responses_NNS ._SENT A_DT greater_JJR understanding_NN of_IN memory_NN T_NN cell_NN complexity_NN can_MD lead_VB to_TO potential_JJ therapies_NNS for_IN manipulation_NN of_IN the_DT memory_NN immune_JJ response_NN in_IN vaccine_NN development_NN and_CC autoimmune_JJ ,_, infectious_JJ ,_, and_CC malignant_JJ diseases_NNS ._SENT Abbreviations_NNS :_: Th_NN =_SYM T_NN helper_NN hemagglutinin_NN T_NN cell_NN receptor_NN phycoerythrin_NN antigen-presenting_NN cell_NN intracellular_JJ cytokine_NN staining_VBG 